Athersys, Inc. (ATHX) News

Athersys, Inc. (ATHX): $1.76

-0.03 (-1.40%)

POWR Rating

Component Grades













Add ATHX to Watchlist
Sign Up

Industry: Biotech


of 491

in industry

Filter ATHX News Items

ATHX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATHX News Highlights

  • For ATHX, its 30 day story count is now at 6.
  • Over the past 6 days, the trend for ATHX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ARDS are the most mentioned tickers in articles about ATHX.

Latest ATHX News From Around the Web

Below are the latest news stories about Athersys Inc that investors may wish to consider to help them evaluate ATHX as an investment opportunity.

Are Institutions Heavily Invested In Athersys, Inc.'s (NASDAQ:ATHX) Shares?

Every investor in Athersys, Inc. ( NASDAQ:ATHX ) should be aware of the most powerful shareholder groups. Insiders...

Yahoo | March 27, 2021

Athersys' (ATHX) Management on Q4 Full Year 2020 Results - Earnings Call Transcript

Athersys, Inc. (ATHX) Q4 Full Year 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Karen Hunady – Director-Corporate Communications and Investor Relations B.J. Lehmann – Interim Chief Executive Officer Ivor Macleod – Chief Financial Officer Conference Call Participants Greg Harrison – Bank of America David Hoang...

SA Transcripts on Seeking Alpha | March 26, 2021

Athersys (ATHX) Q4 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Athersys fourth-quarter and full-year 2020 results conference call. As Rob mentioned, I'm Karen Hunady, director of corporate communications and investor relations for Athersys.

Yahoo | March 26, 2021

Athersys EPS beats by $0.32, beats on revenue

Athersys (ATHX): FY GAAP EPS of -$0.11 beats by $0.32.Revenue of $1.27M (+337.9% Y/Y) beats by $0.99M.Press Release...

Seeking Alpha | March 25, 2021

Athersys Announces Financial Results for Fourth Quarter and Full Year 2020

Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.

Yahoo | March 25, 2021

Athersys (NASDAQ:ATHX) versus OrganiGram (NASDAQ:OGI) Head to Head Analysis

OrganiGram (NASDAQ:OGI) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Institutional & Insider Ownership 10.8% of OrganiGram shares are held by institutional investors. Comparatively, 27.9% of Athersys […]

Modern Readers | March 21, 2021

Regenerative Medicine Market Is Expected To Exhibit 32.2% CAGR By 2023 | Medtronic Plc., Athersys, Inc.

Rise in adoption of stem cell technology, rise in application of nanotechnology, increased prevalence of chronic diseases and trauma emergencies, and increasing technological advancements in medical equipment technology are expected to propel the growth of the global regenerative medicine market. Download

OpenPR | March 4, 2021

Athersys to Host Year-End 2020 Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.

Business Wire | March 2, 2021

Athersys Announces CEO Transition

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys

Business Wire | February 16, 2021

Athersys Announces Cooperation Agreement With HEALIOS K.K.

Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

Yahoo | February 16, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7076 seconds.